ReviewInternational journal of molecular sciences2018
Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Rewriting Inflammation in IBD: Lipidomics from Pathogenesis to Clinical Application.Microorganisms · 2026Review
- Metabolomics and lipidomics signature in celiac disease: a narrative review.Clinical and experimental medicine · 2024Review
- Omics and Multi-Omics in IBD: No Integration, No Breakthroughs.International journal of molecular sciences · 2023Review
- Integration and implementation of precision medicine in the multifaceted inflammatory bowel disease.World journal of gastroenterology · 2023Review
- UPLC-QTOF-MS-based lipidomic study of wedelolactone in acute colitis mice induced by dextran sulfate sodium.Heliyon · 2023Article
- Article
- A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review.International journal of molecular sciences · 2023Review
- High Throughput LC-MS Platform for Large Scale Screening of Bioactive Polar Lipids in Human Plasma and Serum.Journal of proteome research · 2022Article
- Label-Free Quantification (LFQ) of Fecal Proteins for Potential Pregnancy Detection in Polar Bears.Life (Basel, Switzerland) · 2022Article
- The foundations and development of lipidomics.Journal of lipid research · 2022Review
- Effects of Formyl Peptide Receptor Agonists AcCells · 2022Article
- Systematic Review of Recent Lipidomics Approaches Toward Inflammatory Bowel Disease.Biomolecules & therapeutics · 2021Review
- Proteomics identifies a novel role of fibrinogen-like protein 1 in Crohn's disease.World journal of gastroenterology · 2021Article
- Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review.Journal of clinical medicine · 2021Article
- Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet's disease from Crohn's disease.Scientific reports · 2021Article
- Inflammatory Bowel Disease-Associated Changes in the Gut: Focus on Kazan Patients.Inflammatory bowel diseases · 2021Article
- Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine.Journal of translational medicine · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) represents a group of progressive disorders characterized by recurrent chronic inflammation of the gut. Ulcerative colitis and Crohn's disease are the major manifestations of IBD. While our understanding of IBD has progressed in recent years, its etiology is far from being fully understood, resulting in suboptimal treatment options. Complementing other biological endpoints, bioanalytical "omics" methods that quantify many biomolecules simultaneously have great potential in the dissection of the complex pathogenesis of IBD. In this review, we focus on the rapidly evolving proteomics and lipidomics technologies and their broad applicability to IBD studies; these range from investigations of immune-regulatory mechanisms and biomarker discovery to studies dissecting host⁻microbiome interactions and the role of intestinal epithelial cells. Future studies can leverage recent advances, including improved analytical methodologies, additional relevant sample types, and integrative multi-omics analyses. Proteomics and lipidomics could effectively accelerate the development of novel targeted treatments and the discovery of complementary biomarkers, enabling continuous monitoring of the treatment response of individual patients; this may allow further refinement of treatment and, ultimately, facilitate a personalized medicine approach to IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.